BioSpace News Archive

GSK reported positive headline data from a pre-specified efficacy interim analysis of the Phase III trial of its RSV vaccine.

Researchers have linked areas of the brain with people who have takotsubo syndrome, also known as broken heart syndrome.

AbbVie announced Friday that its investigational drug navitoclax, when used together with ruxolitinib, eases symptoms in myelofibrosis patients who had not yet been treated with a JAK inhibitor.

Wilmington, Delaware, United States: According to the report, the global coronary stents market was valued at US$ 10.1 Bn in 2020 and is projected to expand at a CAGR of 12.9% from 2021 to 2028.

Wilmington, Delaware, United States: According to the report, the global surgical procedures volume market was valued at US$ 1.73 Bn in 2020 and is anticipated to expand at a CAGR of 5.5% from 2021 to 2028.

Wilmington, Delaware, United States: According to the report, the global radiopharmaceuticals market was valued at US$ 3.9 Bn in 2020 and is projected to expand at a CAGR of 7.3% from 2021 to 2031.

Wilmington, Delaware, United States: The point-of-care diagnostics market is expected to observe good growth prospects during the forecast period of 2016-2024.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with essential thrombocythemia.

Aruvant Sciences announced that Michael W. Kent, M.D., pediatric blood and marrow transplant physician at Atrium Health/Levine Children’s Hospital, is presenting new data on ARU-1801, a one-time gene therapy for individuals with severe sickle cell disease, at the European Hematology Association 2022 Hybrid Congress.

Global Blood Therapeutics, Inc. announced new data from a large multicenter real-world evidence study supporting the clinical use of Oxbryta® for the treatment of sickle cell disease in patients 12 years of age and older.